Biological effects of aminoguanidine: An update

Inflammation Research

Volumn 48, Issue 10, 1999, Pages 509-515

  Nilsson, B O ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Advanced glycosylation end products; Aminoguanidine; Diamine oxidase; NO synthase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINE OXIDASE (COPPER CONTAINING); AMINOGUANIDINE; HISTAMINE; NITRIC OXIDE SYNTHASE; PUTRESCINE;

AGING; ARTERY DISEASE; DIABETES MELLITUS; HEART VENTRICLE HYPERTROPHY; REVIEW;

ADENOSYLMETHIONINE DECARBOXYLASE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; NITRIC OXIDE SYNTHASE;

EID: 0032697984     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050495     Document Type: Review

References (63)

1. Lieber E, Smith GBL. The chemistry of aminoguanidine and related substances. Chem Rev 1939; 25: 213-71.
2. Sculer W. Zur Hemmung der Diaminooxydase (Histaminase). Experientia 1952; 8: 230-2.
3. Brownlee M, Vlassara H, Kooney P, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
4. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-6.
5. Kobayashi Y, Kupelian J, Maudsley DV. Release of diamine oxidase by heparin in the rat. Biochem Pharmacol 1969; 18: 1585-91.
6. Shaff RE, Beaven MA. Turnover and synthesis of diamine oxidase (DAO) in rat tissues. Studies with heparin and cycloheximide. Biochem Pharmacol 1976; 25: 1057-62.
7. Baylin SB, Stevens SA, Shakir KMM. Association of diamine oxidase and ornithine decarboxylase with maturing cells in rapidly proliferating epithelium. Biochim Biophys Acta 1978; 541: 415-9.
8. Shakir KMM, Margolis S, Baylin SB. Localization of histaminase (diamine oxidase) in rat small intestinal mucosa: site of release by heparin. Biochem Pharmacol 1977; 26: 2343-7.
9. Robinson-White A, Baylin SB, Olivecrona T, Beaven MA. Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells. J Clin Invest 1985; 76: 93-100.
10. Houen G, Jörgensen J, Leonardsen L, Larsson LI. Purification and partial characterization of mammalian Cu-dependent amine oxidases. Acta Chem Scand 1993; 47: 902-9.
11. Schwelberger HG, Bodner E. Purification and characterization of diamine oxidase from porcine kidney and intestine. Biochim Biophys Acta 1997; 1340: 152-64.
12. Morel F, Surla A, Vignais PV. Purification of human placenta diamine oxidase. Biochem Biophys Res Commun 1992; 187: 178-86.
13. Novotny WF, Chassande O, Baker M, Lazdunski M, Barbry P. Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues. J Biol Chem 1994; 269: 9921-5.
14. Mizuguchi H, Imamura I, Takemura M, Fukui H. Purification and characterization of diamine oxidase (histaminase) from rat small intestine. J Biochem 1994; 116: 631-5.
15. Mu D, Medzihradszky KF, Adams GW, Mayer P, Hines WM, Burlingame AL, et al. Primary structures for a mammalian cellular and serum copper amine oxidase. J Biol Chem 1994; 269: 9926-32.
16. Chassande O, Renard S, Barbry P, Lazdunski M. The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem 1994; 269: 14484-9.
17. Zeller EA. Diamine Oxidases. In: Boyer PD, Lardy H, Myrbäck K, editors. The Enzymes. vol. 8. New York: Academic Press, 1963: 314-35.
18. Crabbe MJC, Childs RE, Bardsley WG. Time-dependent inhibition of diamine oxidase by carbonyl-group reagents and urea. Eur J Biochem 1975; 60: 325-33.
19. Beaven M, Roderick NB. Impromidine, a potent inhibitor of histamine methyltransferase (HMT) and diamine oxidase (DAO). Biochem Pharmacol 1980; 29: 2897-900.
20. Tamura H, Horiike K, Fukuda H, Watanabe T. Kinetic studies on the inhibition mechanism of diamine oxidase from porcine kidney by aminoguanidine. J Biochem 1989; 105: 299-306.
21. Bieganski T, Osinska Z, Maslinski C. Inhibition of plant and mammalian diamine oxidases by hydrazine and guanidine compounds. Int J Biochem 1982; 14: 949-53.
22. Schmutzler W, Goldschmidt O, Bethge KP, Knop J. The release of guinea pig-liver histaminase and some of its properties. Int Arch Allergy 1966; 36: 45-55.
23. Suetsugu T. Enzymic properties of diamine oxidase from hog kidney. Jpn J Pharmacol 1974; 24: 141-9.
24. Beaven MA, Schaff RE. Study of the relationship of histaminase and diamine oxidase activities in various rat tissues and plasma by sensitive isotopic assay procedure. Biochem Pharmacol 1975; 24: 979-84.
25. Bruun L, Houen G. In situ detection of diamine oxidase activity using enhanced chemiluminescence. Anal Biochem 1996; 233: 130-6.
26. Gahl WA, Pitot HC. Polyamine degradation in foetal and adult bovine serum. Biochem J 1982; 202: 603-11.
27. Lindell S-E, Nilsson K, Roos B-E, Westling H. The effect of enzyme inhibitors on histamine catabolism in man. Br J Pharmacol 1960; 15: 351-5.
28. Arunlakshana O, Mongar JL, Schild HO. Potentiation of pharmacological effects of histamine by histaminase inhibitors. J Physiol 1954; 123: 32-54.
29. Nilsson B-O, Kockum I, Rosengren E. Effects of aminoguanidine and L-NAME on histamine-induced blood pressure drop in the rat. Acta Physiol Scand 1997; 161: 339-44.
30. Schayer RW. Catabolism of physiological quantities of histamine in vivo. Physiol Rev 1959; 39: 116-26.
31. Bergmark J, Granérus G. Ion exchange chromatography for quantitative analysis of radioactive histamine metabolites in human urine. Scand J Clin Lab Invest 1974; 34: 365-73.
32. 14C-histamine elimination from the blood of pregnant and non-pregnant women with special reference to the uterus. Acta Obstet Gynecol Scand 1963; 42 (Suppl I): 3-25.
33. Lindberg S, Törnqvist Å. The inhibitory effect of aminoguanidine on histamine catabolism in human pregnancy. Acta Obstet Gynecol Scand 1966; 45: 131-9.
34. Kahlson G, Rosengren E. New approaches to the physiology of histamine. Physiol Rev 1968; 48: 155-96.
35. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht C-D, Feussner K-D. Distribution and properties of human intestinal diamine oxidase and its relevance for histamine catabolism. Biochim Biophys Acta 1983; 756: 196-203.
36. Sattler J, Häfner D, Klotter H-J, Lorenz W, Wagner PK. Food-induced histaminosis as an epidemiological problem: plasma histamine elevation and haemodynamic alterations after oral histamine administration and blockade of diamine oxidase (DAO). Agents Actions 1988; 23: 361-5.
37. Nilsson B-O, Kockum I, Rosengren E. Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine. Inflamm Res 1996; 45: 513-8.
38. Sessa A, Perin A. Diamine oxidase in relation to diamine and polyamine metabolism. Agents Actions 1994; 43: 69-77.
39. Furchgott RF, Zawadzski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
40. Moncada S, Palmer RMJ, Higgs FA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
41. Hasan K, Heesen B-J, Corbett JA, McDaniel ML, Chang K, Allison W, et al. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993; 249: 101-6.
42. Pieper GM, Moore-Hilton G, Roza AM. Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Life Sci 1996; 58: 147-52.
43. Laszlo F, Evans SM, Whittle BJR. Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase in rat intestinal microvasculature in vivo. Eur J Pharmacol 1995; 272: 169-75.
44. Lopez-Belmonte J, Whittle BJR. Aminoguanidine-provoked leukocyte adherence to rat mesenterial venules: role of constitutive nitric oxide synthase inhibition. Br J Pharmacol 1995; 116: 2710-4.
45. Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. J Biol Chem 1991; 266: 22789-91.
46. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991; 88: 7773-7.
47. Moss DW, Wei X, Liew FY, Moncada S, Charles IG. Enzymatic characterisation of recombinant murine inducible nitric oxide synthase. Eur J Pharmacol 1995; 289: 41-8.
48. Crack PJ, Tetaz T, Smith AI. Purification, characterization and distribution of ovine neuronal nitric oxide synthase. Comp Biochem Physiol 1998; 120: 727-33.
49. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
50. Li Y-M, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996; 93: 3902-7.
51. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li Y-M, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-8.
52. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-9.
53. Tang SS, Chichester CO, Kagan HM. Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors. Connect Tissue Res 1989; 19: 93-103.
54. Seyer-Hansen M, Andreassen TT, Oxlund H, Jorgensen PH. The influence of aminoguanidine on borohydride reducible collagen cross-links and wound strength. Connect Tissue Res 1991; 26: 181-6.
55. Sajithal GB, Pandarinathan C, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1998; 1407: 215-24.
56. Ino-ue M, Ohgiya N, Yamamoto M. Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats. Brain Res 1998; 800: 319-22.
57. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992; 89: 6876-80.
58. Wolffenbuttel BHR, Huijberts MSP. Aminoguanidine, a potential drug for the treatment of diabetic complications. Neth J Med 1993; 42: 205-8.
59. Corman B, Duriez M, Poitevin P, Heudes D, Bruneval P, Tedgui A, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998; 95: 1301-6.
60. Tabor CW, Tabor H. Polyamines. Ann Rev Biochem 1984; 53: 749-90.
61. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986; 234: 249-62.
62. Stjernborg L, Persson L. Stabilization of S-adenosylmethionine decarboxylase by aminoguanidine. Biochem Pharmacol 1993; 45: 1174-6.
63. Svensson F, Mett H, Persson L. CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Biochem J 1997; 322: 297-302.